Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

Abstract: Methods according to the present invention decolorize a polymer by mixing a solution of the polymer with a photocatalyst and exposing the mixture to ultraviolet light; by way of non-limiting example, the polymer may be a star polymer and the photocatalyst may be titanium dioxide. Methods according to the present invention also utilize a metal scavenger, in some embodiments a solid-phase metal scavenger, to remove a metal catalyst from a polymer solution; by way of non-limiting example, the metal catalyst may be a tin catalyst. The decolorization methods and the catalyst removal methods of the present invention may be practiced separately, sequentially in any order, or simultaneously.

Abstract: The present disclosure generally relates to pharmaceutical corticosteroid compositions, and methods of making the same.

Abstract: A method and system for use in the transportation, sterilization and handling of syringe barrels includes a tray having an array of apertures. The tray comprises features for interfacing with other features such as bins whereby the tray is supported generally horizontally and one or more syringes may be lowered into the tray.

Abstract: Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro-organisms. For example, when applied topically, proguanil is particularly effective against Propionibacterium acnes, a bacteria that causes acne; Corynebacterium minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a bacteria that causes vaginosis; Trichomonas vaginalis, a protozoan that causes trichomoniasis and C. albicans, a fungus (a form of yeast).

Abstract: The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w/w) to about 1.50% (w/w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic buffered pH value for the composition in the range of about 5.0 to about 6.0. The present invention also provides for a method for inhibiting a microorganism. The method includes contacting a microorganism with an effective amount of the composition of the present invention, for a period of time effective to inhibit the microorganism. The present invention also provides for a method for treating bacterial vaginosis in a human patient. The method includes intravaginal administration to a patient in need of such treatment an effective amount of the composition the present invention.